Nexthera Capital LP boosted its stake in shares of Shire PLC (NASDAQ:SHPG) by 132.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 161,949 shares of the biopharmaceutical company’s stock after buying an additional 92,301 shares during the quarter. Shire makes up approximately 4.6% of Nexthera Capital LP’s portfolio, making the stock its 2nd largest holding. Nexthera Capital LP’s holdings in Shire were worth $25,122,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. SeaCrest Wealth Management LLC bought a new position in Shire during the fourth quarter worth about $107,000. Avestar Capital LLC bought a new position in Shire during the fourth quarter worth about $116,000. Amica Retiree Medical Trust bought a new position in Shire during the fourth quarter worth about $120,000. BB&T Investment Services Inc. boosted its position in Shire by 1,672.3% during the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 786 shares during the period. Finally, Steward Partners Investment Advisory LLC bought a new position in Shire during the third quarter worth about $159,000. Institutional investors own 19.75% of the company’s stock.
Shire PLC (SHPG) opened at $132.99 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.97 and a quick ratio of 0.55. Shire PLC has a 1 year low of $123.73 and a 1 year high of $192.15. The company has a market cap of $40,486.03, a P/E ratio of 9.47, a PEG ratio of 0.77 and a beta of 1.44.
The company also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be given a $0.8937 dividend. This is a positive change from Shire’s previous semiannual dividend of $0.15. This represents a dividend yield of 1.33%. The ex-dividend date is Thursday, March 8th. Shire’s dividend payout ratio (DPR) is 7.47%.
A number of brokerages have weighed in on SHPG. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Wednesday, March 7th. BidaskClub upgraded shares of Shire from a “strong sell” rating to a “sell” rating in a research report on Friday, March 2nd. SunTrust Banks cut their target price on shares of Shire to $190.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Shire in a research report on Tuesday, February 20th. Finally, Royal Bank of Canada cut their target price on shares of Shire to $181.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Shire has an average rating of “Buy” and a consensus price target of $204.00.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.